Generics

Rocuronium Bromide injection is part of Fresenius Kabi's +RFID portfolio of smart-labeled medications.

The partnership agreement includes proposed biosimilars to Simponi, Entyvio and three additional early-stage undisclosed biosimilar candidates.

Endo will commercialize the product through its Par sterile products business and expects to begin shipping in summer 2023.

Yuflyma is FDA-approved to treat eight conditions, including Crohn’s disease and ulcerative colitis.

Prednisolone tablets are indicated for a wide variety of disorders.

Upsher-Smith now offers dicyclomine hydrochloride in tablet and capsule forms.

The case involves "skinny labels," which allow generic drugmakers to avoid patent lawsuits if a generic drug's label omits potentially infringing uses of a brand-name drug, per a Reuters report.

Fylnetra is used to treat neutropenia, which is commonly experienced by patients undergoing chemotherapy.

Aurigene is investing $40 million in an R&D and pilot scale facility as a first step toward a series of strategic investments.

Phenoxybenzamine hydrochloride capsules are indicated in the treatment of pheochromocytoma, to control episodes of hypertension and sweating.

Docetaxel injection is a microtubule inhibitor indicated for treating patients with several types of cancer after failure of prior chemotherapy.

Sandoz and Just - Evotec Biologics are partnering to develop and manufacture multiple biosimilars with an option for expansion.